Cincinnati, Ohio
CNS clinical trials in Cincinnati, OH
72 CNS studies are recruiting participants at sites in Cincinnati as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Cincinnati at a glance
- 72 studies are recruiting at a site in Cincinnati.
- By phase: Phase 1 (1), Phase 1/2 (1), Phase 2 (5), Phase 3 (36), Phase 4 (8), No phase (12), Observational (9). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (47), university, hospital or other (24), government (1).
- By research area: Depression (19), Migraine (14), ADHD (9), Multiple Sclerosis (8), Parkinson's Disease (8), Epilepsy (5), Schizophrenia (5), Bipolar Disorder (4).
- Most recent update to one of these records: November 16, 2026.
Depression studies recruiting in Cincinnati
Basic details from each study's public record (the 30 most recently updated of 72). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus
- No phase
- Ages 12 to 22
- All sexes
- Sponsor
- Michigan State University
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT06232304 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study site
- University of Cincinnati Cancer Center-UC Medical Center
- Registry record
- NCT06748222 · updated
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- University of Cincinnati Medical Center
- Registry record
- NCT05850689 · updated
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
- Phase 3
- Ages 10 to 17
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- University of Cincinnati Medical Center
- Registry record
- NCT06372964 · updated
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Patient Priority Clinical Sites LLC
- Registry record
- NCT06559306 · updated
TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age
- Observational
- From 18 months, up to 11 years
- All sexes
- Sponsor
- State University of New York at Buffalo
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT07048574 · updated
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Phase 3
- Ages 12 to 17
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- University of Cincinnati
- Registry record
- NCT07227454 · updated
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Patient Priority Clinical Sites LLC
- Registry record
- NCT07573176 · updated
Study of ALTO-300 in MDD
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Alto Neuroscience
- Registry record
- NCT05922878 · updated
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
- Phase 2
- Ages 18 to 75
- All sexes
- Sponsor
- Alto Neuroscience
- Registry record
- NCT07553637 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Schizophrenia studies recruiting in Cincinnati
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Phase 3
- Ages 13 to 17
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- University of Cincinnati Dept of Psychiatry and Behavioral Neuroscience
- Registry record
- NCT07288567 · updated
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Phase 3
- Ages 5 to 17
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Study site
- University of Cincinnati Cancer Institute
- Registry record
- NCT07424404 · updated
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Phase 3
- Ages 5 to 17
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- University of Cincinnati Medical Center
- Registry record
- NCT06229210 · updated
Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Bipolar disorder studies recruiting in Cincinnati
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- University of Cincinnati Medical Center
- Registry record
- NCT06951711 · updated
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- University of Cincinnati Medical Center
- Registry record
- NCT06929273 · updated
Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Cincinnati, OH on ClinicalTrials.gov.
ADHD studies recruiting in Cincinnati
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Study site
- Patient Priority Clinical Trials
- Registry record
- NCT07759154 · updated
Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Parkinson's disease studies recruiting in Cincinnati
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- AstraZeneca
- Registry record
- NCT06989112 · updated
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103)
- Registry record
- NCT06345729 · updated
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Cincinnati Medical Center ( Site 5013)
- Registry record
- NCT06952504 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027)
- Registry record
- NCT06966700 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Cincinnati Medical Center ( Site 0119)
- Registry record
- NCT06623422 · updated
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 5020)
- Registry record
- NCT07216703 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Multiple sclerosis (MS) studies recruiting in Cincinnati
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- TG Therapeutics, Inc.
- Study site
- TG Therapeutics Investigational Trial Site
- Registry record
- NCT06433752 · updated
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Celgene
- Study site
- University of Cincinnati Medical Center
- Registry record
- NCT06782490 · updated
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Phase 3
- Ages 40 to 70
- All sexes
- Sponsor
- Novartis Pharmaceuticals
- Study site
- Univ of Cincinnati Medical Center
- Registry record
- NCT06846281 · updated
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- TG Therapeutics, Inc.
- Study site
- TG Therapeutics Investigational Trial Site
- Registry record
- NCT05877963 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Epilepsy studies recruiting in Cincinnati
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
- Phase 3
- Ages 2 and older
- All sexes
- Sponsor
- Epygenix
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT04462770 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Migraine studies recruiting in Cincinnati
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Headache Center of Hope
- Registry record
- NCT07816367 · updated
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Phase 3
- Ages 6 to 17
- All sexes
- Sponsor
- Pfizer
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT04649242 · updated
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
- Phase 3
- Ages 6 to 17
- All sexes
- Sponsor
- Pfizer
- Study site
- Cincinnati Children's Hospital
- Registry record
- NCT04743141 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Ask about studies near Cincinnati
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Ohio
All Ohio locations
175 studies recruiting across 37 cities.
Cleveland
55 studies recruiting.
Columbus
54 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections